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هبوط سكر الدم بني مرضى السكر الذين يتلقون عالجاً باإلنسولني
جمموعة اإلمارات العربية املتحدة لدراسة أداة تقييم هبوط سكر الدم يف العمليات الدولية
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abstract: Objectives: This study aimed to evaluate the incidence of hypoglycaemia among insulin-treated patients 
with type 1 diabetes mellitus (T1DM) or type 2 diabetes mellitus (T2DM) from the United Arab Emirates (UAE) cohort of 
the non-interventional International Operations-Hypoglycaemia Assessment Tool study. Methods: This cross-sectional 
observational study took place at 25 patient care centres in the UAE from October 2014 to May 2015. All adult patients 
with T1DM or T2DM who had been treated with insulin for >12 months were included. Self-assessment questionnaires 
and patient diaries were used to determine the incidence of documented hypoglycaemia both prospectively (four weeks 
after baseline) and retrospectively (six months and four weeks before baseline for severe and non-severe hypoglycaemic 
events, respectively). Results: A total of 325 patients were enrolled in the study, of which 82 (25.2%) had T1DM and 
243 (74.8%) had T2DM. Among patients with T1DM, 71.4% reported hypoglycaemic events retrospectively, with an 
incidence rate (IR) of 102.8 events per patient-year (PY), while 95% reported hypoglycaemic events prospectively, with an 
IR of 63.1 events per PY. Additionally, 56.3% of patients with T2DM reported hypoglycaemic events retrospectively, with 
an IR of 42.2 events per PY, while 91.9% reported hypoglycaemic events prospectively, with an IR of 33.3 events per PY. 
Conclusion: The prevalence and incidence of hypoglycaemia were high among insulin-treated patients with T1DM and 
T2DM in the UAE. Individualised glycaemic goals, patient education and blood glucose monitoring may help to reduce 
the incidence of hypoglycaemia in this population.
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ال�شكر من  اأو مر�شى  الذين يتلقون عالجًا بالإن�شولني  الأول  النوع  ال�شكر من  الدم يف مر�شى  هبوط �شكر  الهدف: تقييم حدوث  امللخ�ص: 
النوع الثاين يف درا�شة الأداة غريالتداخلية لتقييم هبوط �شكر الدم يف العمليات الدولية. الطريقة: اأجريت هذه الدرا�شة املقطعية الر�شدية 
يف 25 مركزا للرعاية الطبية يف الإمارات العربية املتحدة من اأكتوبر 2014 اىل مايو 2015. جميع مر�شى ال�شكر من النوع الأول اأو مر�شى 
ال�شكر من النوع الثاين الذين يتلقون عالجًا بالإن�شولني منذ 12> �شهراً �شاركو يف الدرا�شة. اأكمل امل�شاركون يف الدرا�شة ا�شتبيان التقييم 
الذاتي املكون من جزئني ويوميات املر�شى الذين �شجلوا انخفا�شًا يف �شكر الدم باأثر م�شتقبلي )4 اأ�شابيع بعد نقطة البداية( وباأثر رجعي 
)6 اأ�شهر/4 اأ�شابيع قبل نقطة البداية(. النتائج: مت ت�شجيل اإجمايل 325 مري�شا �شاركو يف هذه الدرا�شة منهمً 82 )%25.2( لديهم �شكري من 
النوع الأول و 243 )%74.8( لدمي �شكري من النوع الثاين. يف مر�شى ال�شكر من النوع الأول، ظهرت حالت هبوط �شكر الدم يف %71.4 من 
املر�شى مبعدل حدوث: 102.8 حالة كل عام يف التقييم باأثر رجعي بينما ظهرت حالت هبوط �شكر الدم بن�شبة %95 يف املر�شى مبعدل 
حدوث: 63.1 حالة كل عام يف التقييم ال�شتباقي. يف مر�شى ال�شكر من النوع الثاين، ظهرت حالت هبوط �شكر الدم يف %56.3 من املر�شى 
مبعدل حدوث: 42.2 حالة كل عام يف التقييم باأثر رجعي بينما ظهرت حالت نق�س �شكر الدم بن�شبة %91.9 يف املر�شى مبعدل حدوث: 
33.3 حالة كل عام يف التقييم ال�شتباقي. اخلال�صة: كان انت�شار وحدوث هبوط يف �شكر الدم مرتفعًا بني مر�شى ال�شكر من النوع الأول 
ومر�شى ال�شكر من النوع الثاين الذين يعاجلون بالإن�شولني يف الإمارات العربية املتحدة مما ي�شبب زيادة يف ا�شتخدام الرعاية ال�شحية، و 
قد ي�شاعد و�شع اأهداف فردية لن�شبة ال�شكر يف الدم، وتعليم املر�شى، ومراقبة ن�شبة اجللوكوز يف الدم يف احلد من حدوث هبوط يف �شكر الدم.
الكلمات املفتاحية: هبوط �شكر الدم؛ اإن�شولني؛ مر�س ال�شكر من النوع الأول؛ مر�س ال�شكر من النوع الثاين؛ الإمارات العربية املتحدة.
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Hypoglycaemia is a condition in whichblood glucose (BG) levels drop below normal levels (3.9–7.1 mmol/L).1 Approximately 90% of 
all patients treated with insulin experience hypoglycaemic 
episodes/events.2 Complex regimes and glycaemic 
restrictions have been shown to increase the risk of 
hypoglycaemia, with severe hypoglycaemic events asso- 
ciated with increased mortality and morbidity.3 Hypogly- 
caemia also carries an economic burden, impacting patient 
productivity and disease management and utilising valu- 
able healthcare resources.4
According to a recent meta-analysis, hypoglycaemia 
is prevalent among patients with type 2 diabetes mellitus 
(T2DM), thus necessitating an individualised approach 
to treatment and patient education.5 The Canadian Hypo- 
glycaemia Assessment Tool Program revealed high rates 
of hypoglycaemia among insulin-treated patients; the 
researchers advocated for the identification of high-risk 
insulin-treated patients in order to reduce the incidence 
of hypoglycaemia in this patient group.6 In Germany, 
a patient-reported study revealed high rates of non-
severe hypoglycaemic events among those with type 1 
diabetes mellitus (T1DM) or insulin-treated T2DM.7 
Unfortunately, it can be difficult to establish the actual 
rate of hypoglycaemic events as the majority of publ- 
ished data are based on the results of randomised contr-
olled clinical trials (RCTs), which usually investigate the 
clinical efficacy and safety of certain drugs.8,9 Moreover, 
patients at higher risk of hypoglycaemia are often excl-
uded from RCTs.10 
In 2017, the International Operations-Hypoglyc-
aemia Assessment Tool (IO-HAT) study was conducted 
to determine the prevalence and incidence rates (IRs) 
of hypoglycaemic events among 7,289 insulin-treated 
patients with T1DM and T2DM in Bangladesh, Col-
ombia, Egypt, Indonesia, the Philippines, Singapore, 
South Africa, Turkey and the United Arab Emirates 
(UAE).11 The IO-HAT study was itself based on data 
gathered as part of a larger investigation of 27,585 adult 
patients from 24 countries.12 The current study aimed 
to determine the incidence of hypoglycaemia among 
the UAE cohort of the IO-HAT study.11 In addition, 
the patients’ knowledge of and attitudes towards hypo-
glycaemia were assessed, as well as the relationship bet- 
ween the incidence of hypoglycaemia and insulin reg-
imens and glycaemic control, as determined by baseline 
glycated haemoglobin (HbA1c) measurements.
Methods
This cross-sectional non-interventional study was cond- 
ucted at 25 patient care centres in the UAE between 
October 2014 and May 2015. All patients with T1DM 
or T2DM who were ≥18 years old at baseline and 
who had been treated with an insulin regimen for >12 
months were included. Patients were enrolled in the 
study according to a consecutive sampling method 
during routine clinical consultation with their health-
care providers. As per the guidelines of the American 
Diabetes Association, severe hypoglycaemia was defined 
as an event of confirmed hypoglycaemia requiring the 
assistance of another individual to actively administer 
carbohydrate or glucagon interventions or take resusc- 
itative action.13 Non-severe events were defined as sympt- 
omatic events not requiring biological confirmation and 
managed by the patient alone. Nocturnal hypoglycaemia 
was defined as an event occurring between midnight 
and 6 am.13
Self-reported events of hypoglycaemia were docu- 
mented by participants using a two-part self-assessment 
questionnaire and patient diaries. The primary endpoint 
of the study was the percentage of patients experiencing 
at least one hypoglycaemic event during a four-week 
prospective period; events were recorded in patient 
diaries completed over a four week period from base- 
line. The secondary endpoints included the IRs of hypo- 
glycaemia prospectively (four weeks after baseline) 
and retrospectively (six months and four weeks before 
baseline for severe and non-severe events, respectively); 
these were determined according to a two-part self-
assessment questionnaire, with the first part completed 
by the participants at baseline and the second part 
completed four weeks later [Figure 1]. The two-part 
self-assessment questionnaire and patient diaries were 
translated into local languages and all acquired data were 
subsequently translated back into English for analytical 
purposes.
Other secondary endpoints included the patients’ 
knowledge, awareness and fear of and attitudes towards 
hypoglycaemia and the relationship between the inc- 
idence of hypoglycaemia and insulin regimens and gly- 
 
Figure 1: Diagram illustrating the design of the study.
SH = severe hypoglycaemia; NSH = non-severe hypoglycaemia; 
SAQ = self-assessment questionnaire.
Figure adapted with permission from: Emral R, Pathan F, Cortés CA, 
El-Hefnawy MH, Goh SY, Gómez AM, et al. Self-reported hypo-
glycemia in insulin-treated patients with diabetes: Results from an 
international survey on 7289 patients from nine countries.11
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caemic control. Awareness of hypoglycaemia was eval- 
uated according to the patients’ responses to the question 
‘Do you have symptoms when you have low sugar levels?’, 
in which the response ‘usually’ denoted impaired aware- 
ness and ‘occasionally’ or ‘never’ denoted severely imp- 
aired awareness. Fear of hypoglycaemia was self-assessed 
by patients on a scale of 0–10, where 0 denoted ‘not 
afraid at all’ and 10 was ‘absolutely terrified’. Glycaemic 
control was determined by baseline HbA1c measurements, 
with percentages of >9%, 7–9% and <7% indicating poor, 
suboptimal and good glycaemic control, respectively. 
Comprehensive details of the design of the IO-HAT study 
and the procedures used for the assessment of hypo- 
glycaemia have been previously reported by Emral et al.11
The percentages of patients experiencing at least 
one hypoglycaemic event during the four-week prosp- 
ective period were calculated along with 95% confidence 
intervals (CIs). Rates of hypoglycaemia were deemed 
equivalent in the retrospective and prospective periods 
according to two-sided statistical tests with the level of 
statistical significance set at P ≤0.050. The IRs of hypo-
glycaemia were calculated as the total number of events 
per patient-year (PY) divided by the total follow-up 
time in PYs along with 95% CIs. The difference in the 
reported incidence of hypoglycaemia was calculated 
using a negative binomial regression model, including 
a single binary covariate for two periods (four weeks 
before baseline and four weeks after baseline), specifying 
a logged exposure time as the offset term and using 
robust standard error to adjust for repeated measure-
ments and the potential dependence between patients 
sharing the same site (site-level clustering).
This study was approved by the local ethics 
committee at each patient care centre, including the 
Al Qassimi Hospital Research & Ethics Committee, 
Sharjah (#154/2014-09-21), the Dubai Scientific Research 
Ethics Committee, Dubai (#DSREC-12/2014-03), the 
Institutional Review Board/Research Ethics Committee 
of Sheikh Khalifa Medical City, Abu Dhabi (#REC-0- 
5.02.2015 RS-352) and the Gulf Medical University 
Ethics Committee, Ajman (#NovoNordisk/1/30032015). 
All study procedures were conducted in accordance 
with the guidelines of the International Society for 
Pharmacoepidemiology and the ethical standards of the 
revised Declaration of Helsinki.14 All patients provided 
informed consent prior to their participation in the 
study.
Results
A total of 325 patients were enrolled in the study at 
baseline, of which 82 (25.2%) had T1DM and 243 (74.8%) 
had T2DM. Overall, the mean age of patients with T2DM 
was higher than those with T1DM (52.4 ± 10.4 years 
versus 31.5 ± 11.6 years). In addition, the mean duration 
Table 1: Characteristics of insulin-treated patients with type 1 






Mean age in years ± SD 31.5 ± 11.6 52.4 ± 10.4
Male gender 43 (52.4) 144 (59.3)
Mean diabetes duration in 
years ± SD 
13.5 ± 8.7 14.5 ± 7.5
Mean insulin duration in 
years ±SD 
12.6 ± 8.6 6.8 ± 6.0
Mean HbA1c % ± SD 8.6 ± 1.9 8.6 ± 1.6
Mean FBG in mmol/L ± SD 7.7 ± 3.7 7.7 ± 2.4
Mean PPG in mmol/L ± SD 9.6 ± 3.5 11.1 ± 3.9







Myocardial infarction 0 11.9
None 63.4 39.1
Oral antidiabetic medications
α-glucosidase inhibitors 1 (1.2) 7 (2.9)
Metformin 9 (11) 169 (69.5)
DPP-4 inhibitors 5 (6.1) 115 (47.3)
GLP-1 analogues 1 (1.2) 18 (7.4)
Metiglinides/glinides 0 (0) 3 (1.2)
SGLT2 inhibitors 1 (1.2) 23 (9.5)
Sulfonylureas 2 (2.4) 68 (28)
Thiazolidinediones 0 (0) 8 (3.3)
Other 1 (1.2) 12 (4.9)
None 68 (82.9) 30 (12.3)
Insulin regimen†
SA 2 (4) 7 (2.2)
LA 0 (0) 77 (24.1)
Premixed 6 (7.3) 73 (30)
Both SA and LA 62 (75.6) 92 (37.9)
Both SA and premixed 2 (2.4) 7 (2.9)
Both LA and premixed 1 (1.2) 4 (1.6)
Ability to self-assess BG levels†
Yes 72 (87.8) 221 (90.9)
No 3 (3.7) 18 (7.4)
Unsure 6 (7.3) 4 (1.6)
T1DM = type 1 diabetes mellitus; T2DM = type 2 diabetes mellitus; 
SD = standard deviation; HbA1c = glycated haemoglobin; FBG = fasting 
blood glucose; PPG = post-prandial glucose; BMI = body mass index; 
PVD = peripheral vascular disease; DPP = dipeptidyl peptidase; GLP = 
glucagon-like peptide; SGLT2 = sodium-glucose cotransporter-2; SA = 
short-acting; LA = long-acting.  *Percentages do not add up to 100% as 
some patients may have had more than one illness.  †Percentages are 
based on the number of patients with available data.
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of insulin use was shorter among patients with T2DM 
compared to those with T1DM (6.8 ± 6.0 years versus 
12.6 ± 8.6 years). However, mean baseline HbA1c perc- 
entages were similar in both groups (8.6 ± 1.6% versus 
8.6 ± 1.9%) [Table 1]. A total of 262 patients completed the 
second part of the questionnaire after the prospective 
period had elapsed. Of these, 60 (22.9%) had T1DM and 
202 (77.1%) had T2DM. 
Nearly all patients with T1DM (95%; 95% CI: 
86.1–99.0%) and T2DM (91.9%; 95% CI: 87.1–95.3%) 
reported at least one hypoglycaemic event during 
the prospective period. In contrast, 71.4% (95% CI: 
60.0–81.2%) of patients with T1DM and 56.3% (95% CI: 
49.7–62.7%) of patients with T2DM experienced hypo-
glycaemic events in the retrospective period. Nocturnal 
hypoglycaemic events were reported in 56.7% 
(95% CI: 44.0–68.8%) and 35.6% (95% CI: 29.3–42.3%) 
of patients with T1DM and T2DM, respectively, in the 
retrospective period. During the prospective period, 
43.6% (95% CI: 30.3–57.7%) of patients with T1DM 
and 33.5% (95% CI: 26.8–40.7%) of patients with T2DM 
reported nocturnal hypoglycaemic events. Severe hypo- 
glycaemic events were experienced by 39.5% (95% CI: 
28.4–51.4%) and 44% (95% CI: 37.6–50.6%) of patients 
with T1DM and T2DM, respectively, in the retro-
spective period. In the prospective period, 61.7% 
(95% CI: 54.4–68.5%) of T2DM patients and 36.7% 
(95% CI: 24.6–50.1%) of T1DM patients reported severe 
hypoglycaemic events.
Among patients with T1DM, the IR of any hypo-
glycaemic event was higher in the retrospective period 
than the prospective period, although this difference was 
not significant (102.8 events per PY, 95% CI: 94.8–11.3 
events per PY versus 63.1 events per PY, 95% CI: 
56.0–70.7 events per PY; P = 0.093). The IR of nocturnal 
hypoglycaemia among patients with T1DM was signif-
icantly higher in the retrospective period compared to 
the prospective period (59.2 events per PY, 95% CI: 
52.7–66.2 events per PY versus 12.6 events per PY, 
95% CI: 9.4–16.4 events per PY; P <0.001). However, 
 
Figure 2: Incidence rates of hypoglycaemia among 
insulin-treated patients with (A) type 1 and (B) type 2 
diabetes mellitus in the United Arab Emirates (N = 325). 
Hypoglycaemic events were assessed retrospectively 
over a four-week and six-month period (for nocturnal/
non-severe and severe hypoglycaemia, respectively) and 
prospectively over a four-week period.
PY = patient-year; RR = risk ratio.
 
Figure 3: Incidence rates of (A) any, (B) nocturnal and 
(C) severe hypoglycaemia according to insulin regimen 
among patients with type 2 diabetes mellitus in the 
United Arab Emirates (N = 243). Hypoglycaemic events 
were assessed retrospectively over a four-week and six-
month period (for nocturnal/non-severe and severe 
hypoglycaemia, respectively) and prospectively over a 
four-week period.
PY = patient-year; SA = short-acting; LA = long-acting.
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the IR of severe hypoglycaemia in this group showed 
a non-significant increase in the prospective period 
compared to the retrospective period (9.4 events per 
PY, 95% CI: 6.8–12.6 events per PY versus 3.2 events 
per PY, 95% CI: 2.6–3.8 events per PY; P = 0.682) 
[Figure 2A].
Similarly, the IR of any hypoglycaemic events 
among patients with T2DM was slightly higher in 
the retrospective period compared to the prospective 
period (42.2 events per PY, 95% CI: 39.2–45.2 events 
per PY versus 33.3 events per PY, 95% CI: 30.4–36.3 
events per PY). In contrast, the IR of severe hypo-
glycaemia was higher in the prospective period 
compared to the retrospective period (10.6 events per 
PY, 95% CI: 9.0–12.4 events per PY versus 2.6 events 
per PY, 95% CI: 2.3–2.9 events per PY); nevertheless, 
both of these differences were non-significant (P = 0.253 
and 0.142, respectively). As with the T1DM patients, 
the IR of nocturnal hypoglycaemia among patients with 
T2DM was significantly higher in the retrospective 
period compared to the prospective period (14.5 events 
per PY, 95% CI: 12.7–16.4 events per PY versus 7.2 
events per PY, 95% CI: 5.9–8.7 events per PY; P <0.001) 
[Figure 2B].
The IRs of any, nocturnal and severe hypoglycaemic 
events were calculated according to insulin regimens. 
For T1DM patients, the greatest IR of any hypoglyc-
aemic events was observed with the use of a premixed 
insulin regimen in the prospective period (208.7 events 
per PY). The greatest IR of nocturnal hypoglycaemic 
events occurred among patients using a combination 
of short- and long-acting insulin regimens in the retro- 
spective period (72.1 events per PY). For severe hypo-
glycaemic events, the greatest IR was observed among 
patients undertaking a long-acting insulin regimen in 
the prospective period (58.7 events PPY). The IRs for 
all types of hypoglycaemic events by insulin regimen 
for patients with T2DM in both the retrospective and 
prospective periods is presented in Figure 3.
No correlation was found between the percentage 
of patients experiencing hypoglycaemic events and glyc- 
aemic control in the prospective and retrospective periods. 
Among patients with T1DM, the majority (73.7%) of any 
hypoglycaemic events in the four-week retrospective 
period was experienced by patients with suboptimal 
glycaemic control; however, the proportion of patients 
experiencing any hypoglycaemic events was higher in 
those with poor glycaemic control compared to those 
with good glycaemic control (63.6% versus 61.5%). 
Among patients with T2DM, 64.8% of patients with 
poor glycaemic control, 54.5% with good glycaemic 
control and 53% with suboptimal glycaemic control 
experienced any hypoglycaemic events.
In terms of their perceptions of how hypoglycaemic 
events impacted the medical system, 5.2% versus 13.6% 
of T1DM patients and 0.5% versus 4.3% of T2DM 
patients reported that the event required hospital 
admission in the prospective period compared to the 
retrospective period. In addition, T1DM patients more 
frequently reported that the event resulted in additional 
telephone contacts retrospectively (16.7% versus 8.6%), 
while more T2DM patients reported this prospectively 
(20.1% versus 16.1%). Furthermore, more patients with 
T1DM undertook increased BG monitoring following 
the event compared to patients with T2DM in both 
the retrospective (54.9% versus 36.2%) and prospective 
(51.7% versus 31.7%) periods. In the retrospective 
period, fewer patients with T2DM compared to those 
Table 2: Actions and perceptions following hypoglycaemic 
events among insulin-treated patients with type 1 and type 






RT PT RT PT
Action following 
event
n = 82 n = 60 n = 243 n = 202
Consulted their 
doctor/nurse




46 (56.1) 27 (45) 146 (60.1) 94 (46.5)
Increased caloric 
intake
21 (25.6) 15 (25) 63 (25.9) 55 (27.2)
Avoided physical 
exercise
11 (13.4) 5 (8.3) 48 (19.8) 44 (21.8)
Reduced insulin 
dose
22 (26.8) 24 (40) 62 (25.5) 65 (32.2)
Skipped insulin 
injections
15 (18.3) 10 (16.7) 54 (22.2) 38 (18.8)
Increased BG 
monitoring 
45 (54.9) 31 (51.7) 88 (36.2) 64 (31.7)
Perceived impact 
of event on the 
medical system




9 (13.6) 3 (5.2) 8 (4.3) 1 (0.5)
Added telephone 
contacts
11 (16.7) 5 (8.6) 30 (16.1) 39 (20.1) 
Perceived 
impact of event 
on work/studies†
n = 63 n = 46 n = 143 n = 126
Took leave 17 (27) 5 (10.9) 16 (11.2) 8 (6.3)
Arrived late 11 (17.5) 6 (13) 13 (9.1) 7 (5.6)
Left early 10 (15.9) 4 (8.7) 9 (6.3) 6 (4.8)
RT = retrospective; PT = prospective; T1DM = type 1 diabetes mellitus; 
T2DM = type 2 diabetes mellitus; BG = blood glucose. *Percentages are 
based on the number of patients with evaluable data. †Only applicable to 
patients who worked/studied.
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with T1DM reported that hypoglycaemic events resulted 
in their absence (11.2% versus 27%), late arrival (9.1% 
versus 17.5%) or early departure (6.3% versus 15.9%) 
from work or studies [Table 2].
Many patients with T1DM (84.2%) and T2DM 
(79.4%) had baseline knowledge of hypoglycaemia before 
being provided with the definition in the first part of the 
questionnaire. The number of patients defining hypo- 
glycaemic events based on symptoms alone or in con-
junction with BG measurements was comparable in both 
the T1DM and T2DM groups (47.6% versus 49% and 
24.4% versus 29.2%, respectively). However, a small pro- 
portion of both T1DM and T2DM patients used only 
BG measurements to define hypoglycaemia (6.1% versus 
2.9%). Fewer patients with T1DM had severely impaired 
awareness of hypoglycaemia compared to T2DM patients 
(1.2% versus 5.8%). The mean fear of hypoglycaemia score 
was comparable between the two groups (4.7 ± 3.6 versus 
4.8 ± 3.7) [Table 3].
Discussion
According to the International Diabetes Federation, 425 
million people had diabetes mellitus (DM) in 2017 and 
this number is expected to reach 629 million by 2045.15 
The UAE has one of the world’s highest prevalence 
rates of DM (15.4%), with 40% of those over the age 
of 60 years suffering from the condition and 2.7 new 
cases of T1DM diagnosed per 100,000 children and 
adolescents annually.16–19 By 2045, it is predicted that 
23.4% of the population between 20–79 years old in 
the UAE will have DM.17,18 Therefore, identifying the 
incidence of hypoglycaemic events is paramount in 
order to determine disease burden. However, recent 
studies have detected higher rates of hypoglycaemia in 
real-world settings when compared with the results of 
clinical trials.5,8,20 This may be a result of the stringent 
methodological and design constraints of RCTs, as 
well as the restricted selection of patients, uniform 
treatment approach and insufficient BG monitoring 
which limits the generalisability of such findings to 
routine clinical practice.9–12
As part of the larger IO-HAT study, the current 
study analysed self-reported rates of hypoglycaemic 
events among a cohort of insulin-treated DM patients 
from patient care centres in the UAE.11 Although 
higher rates of any or nocturnal hypoglycaemic events 
were reported in the current study during the retro-
spective period compared to the prospective period 
for both T1DM and T2DM patients, higher rates of 
severe hypoglycaemic events were reported prospect-
ively in both periods; this may indicate that severe hypo- 
glycaemic events were underreported by participants 
during the retrospective period. Gubitosi-Klug et al. 
similarly reported a higher incidence of severe hypo-
glycaemia in the prospective period among patients 
with T1DM.21
In the current study, the level of knowledge of 
the definition and symptoms of hypoglycaemia was 
similar to previously reported findings among diabetic 
individuals.19,22 This may be because such patients have 
individualised BG targets, greater experience with BG 
monitoring or have received patient education on this 
topic.23 Fear of hypoglycaemia can have major clinical 
repercussions for DM management. However, in the 
current study, low fear of hypoglycaemia was reported 
among both T1DM and T2DM patients, possibly due 
to adequate hypoglycaemia awareness and glycaemic 
control.24 Nevertheless, patients stated that hypoglycaemic 
events often negatively impacted their work or studies, 
with T1DM patients in particular more frequently 
reporting that such events resulted in absences, arriving 
late or leaving early compared to T1DM patients. 
Previous research also supports the notion that hypo-
glycaemia restricts social or functional activities, incr-
eases absenteeism, impairs punctuality and reduces 
productivity.25,26 
Previous studies have shown that all forms of 
hypoglycaemia are independent of levels of glycaemic 
control.27,28 Increased hypoglycaemic events in patients 
Table 3: Knowledge, awareness and fear of hypoglycaemia among 
insulin-treated patients with type 1 and type 2 diabetes mellitus 






Knowledge of hypo- 
glycaemia at baseline*
69 (84.2) 193 (79.4)
Definition of a hypoglycaemic event
Symptoms 39 (47.6) 119 (49)
BG measurements 5 (6.1) 7 (2.9)
Either symptoms or 
BG measurements
15 (18.3) 26 (10.7)
Both symptoms and 
BG measurements
20 (24.4) 71 (29.2)
Awareness of hypoglycaemia†
Normal 49 (59.8) 133 (54.7)
Impaired 32 (39) 87 (35.8)
Severely impaired 1 (1.2) 14 (5.8)
Mean fear of 
hypoglycaemia ± SD‡
4.7 ± 3.6 4.8 ± 3.7
T1DM = type 1 diabetes mellitus; T2DM = type 2 diabetes mellitus; 
BG = blood glucose; SD = standard deviation. 
*Prior to the first self-assessment questionnaire being administered. 
†Excluding nine patients with T2DM for whom data for this category 
were unavailable. ‡Scored on a scale of 0–10, where 0 denoted ‘not 
afraid at all’ and 10 was ‘absolutely terrified’.
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with higher HbA1c levels may reflect poor self-care 
behaviours as well as aggressive efforts to improve their 
glycaemic control. Lash et al. advocate for increasing 
hypoglycaemia awareness, patient education and shared 
decision-making and the adoption of risk assessment 
and clinical decision-making support tools to support 
management of the condition.29
The current study is subject to certain limitations. 
During the enrolment of eligible patients, the possibility 
of volunteer bias could not be excluded. In addition, due 
to the retrospective design of the study, self-reported 
rates of hypoglycaemia may have been affected by recall 
bias; for example, patients may have under- or over-
reported severe hypoglycaemic events based on the def- 
inition alone, regardless of the severity of their symptoms 
or BG measurements.3 In addition, there may have been 
an overestimation in reported events while adjusting for 
recall bias, as reported rates of hypoglycaemic events 
were higher in patient diaries compared to their responses 
to the second part of the self-assessment questionnaire. 
Nevertheless, precautions were taken to ensure that rates 
of hypoglycaemia were not overreported by following 
the guidelines of the International Society for Pharma-
coepidemiology.14
Conclusion
To the best of the authors’ knowledge, this is the 
first patient-reported dataset of hypoglycaemic events 
among the UAE cohort of the IO-HAT study. These 
findings highlight the high prevalence and incidence 
of hypoglycaemia among insulin-treated patients with 
DM and the potential impact of the condition on 
productivity, health and healthcare resource utilisation. 
Patient education and personalised glycaemic goals may 
help to lower the incidence of all forms of hypoglycaemia 
in this population, thus reducing associated costs to 
the healthcare system.
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